Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults

Noa Eliakim-Raz; Amos Stemmer; Nassem Ghantous; Asaf Ness; Muhammad Awwad; Yaara Leibovici-Weisman; Salomon M Stemmer

doi:10.1001/jamanetworkopen.2022.23090

Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults

JAMA Netw Open. 2022 Jul 1;5(7):e2223090. doi: 10.1001/jamanetworkopen.2022.23090.

Authors

Noa Eliakim-Raz^{1

2}, Amos Stemmer³, Nassem Ghantous^{1

2}, Asaf Ness^{1

2}, Muhammad Awwad^{1

2}, Yaara Leibovici-Weisman^{1

2}, Salomon M Stemmer^{2

4}

Affiliations

¹ Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
² Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel.
⁴ Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.

Abstract

This cohort study evaluates the response to a third and fourth SARS-CoV-2 BNT162b2 vaccine dose among individuals aged 60 years or older by evaluating antispike immunoglobulin G antibody titers before and after each dose.

MeSH terms

Aged
Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines*
COVID-19* / prevention & control
Humans
SARS-CoV-2

Substances

Antibodies, Viral
COVID-19 Vaccines
BNT162 Vaccine